AVITA Announces Office Transitions in Australia and the UK

Avita Announces Office Transitions in Australia and the UK Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 — Avita Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and […]

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights

Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia  Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational  First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]

Avita Medical – Rights Issue Raises $12.4 Million

Avita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]